Losartan

In this video, Xiuning Le, MD, PhD, discusses how she approaches putting together a treatment plan for a patient with EGFR-mutated lung cancer.

Losartan failed to reduce lung injury or improve clinical outcomes in patients hospitalized with COVID-19, researchers reported in JAMA Network Open.

The use of angiotensin II receptor antagonists, particularly generic valsartan, losartan and irbesartan, decreased since being recalled for potentially carcinogenic impurities, according to a research letter published in JAMA.

Treatment with a polypill — generally combining statins, BP-lowering drugs and sometimes aspirin — is not a new concept for CVD. Two recent successful trials have brought the use of a polypill for primary and secondary prevention of CVD into the spotlight again, one of which extended the applicability of the concept to the United States.

Healio and Cardiology Today compiled a list of the most-viewed cardiology posts in September. This month, our readers were interested in recalls of losartan due to impurities, the DAPA-HF and DEFINE-HF studies showing benefit of dapagliflozin (Farxiga, AstraZeneca) in patients with HF regardless of diabetes status, the effect of a salt substitution regimen on hypertension and much more.

The FDA announced it issued a warning letter to Torrent Pharmaceuticals over violations of good manufacturing practice regulations observed during an inspection of a plant producing losartan in India.

Healio and Cardiology Today compiled a list of the most-viewed cardiology posts in September. This month, our readers were interested in recalls of losartan due to impurities, the DAPA-HF and DEFINE-HF studies showing benefit of dapagliflozin (Farxiga, AstraZeneca) in patients with HF regardless of diabetes status, the effect of a salt substitution regimen on hypertension and much more.

Torrent Pharmaceuticals has expanded its voluntary recall of its losartan potassium tablets to include five additional lots due to unacceptable amounts of N-Nitroso-N-methyl-4-aminobutyric acid, or NMBA, according to an FDA press release.

Zantac manufacturer Novartis has stopped the distribution of its heartburn medication across all available markets, including the United States and Canada, Reuters reported.

In a statement released today on safety issues with angiotensin II receptor blockers, the FDA wrote that risk for harm to patients from nitrosamine impurities is likely lower than has been stated in previous estimates, and that the risks of stopping the medications must be considered.